<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321714/" ref="ordinalpos=2876&amp;ncbi_uid=7158349&amp;link_uid=PMC4321714" image-link="/pmc/articles/PMC4321714/figure/Fig6/" class="imagepopup">Figure 6.  From: Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody"> <b>Protein expression of factors related to the p53 signaling pathway in U251 cells treated with HATi II.</b> Western blot analysis of p53 and p21 <b>(A)</b> and factors downstream of the p53 signaling pathway <b>(B, C)</b> in U251 cells treated with HATi II. <b>(D)</b> Western blot analysis confirming siRNA-mediated knockdown of Reprimo. <b>(E)</b> The morphological assay indicated that knockdown of Reprimo markedly reduced cell death in a dose-dependent manner in U251 cells treated with 10 or 20 μmol/l HATi II for 48 h. <b>(F)</b> The hoechst 33342 staining assay indicated that knockdown of Reprimo reduced apoptosis in U259 cells treated with 10 μmol/l HATi II for 48 h compared with control cells; **P &lt; 0.01.</div></div>